We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App




Boston Scientific Acquires Medical Device Company Intera Oncology

By HospiMedica International staff writers
Posted on 26 Nov 2024
Print article
Image: Intera 3000 is the only FDA-approved pump for HAI therapy (Photo courtesy of Intera Oncology)
Image: Intera 3000 is the only FDA-approved pump for HAI therapy (Photo courtesy of Intera Oncology)

Boston Scientific Corporation (Marlborough, MA, USA) has entered into a definitive agreement to acquire Intera Oncology (Newton, MA, USA) which provides the Intera 3000 hepatic artery infusion (HAI) pump and floxuridine – a chemotherapy drug – both of which are approved by the U.S. Food and Drug Administration. Boston Scientific expects to complete the transaction in the first half of 2025, subject to closing conditions.

In the U.S., approximately 1.4 million people are living with primary colorectal cancer, and over 150,000 new cases are diagnosed each year. For about 25% of these patients, the cancer will spread to the liver. The Intera 3000 pump is designed to administer HAI therapy to treat liver tumors, particularly those caused by metastatic colorectal cancer. When patients undergo HAI therapy, the Intera 3000 pump is implanted under the skin, and a catheter is inserted into the hepatic artery, which supplies the liver with oxygenated blood. The pump continuously delivers floxuridine directly to the liver to target tumors that have metastasized, typically from the colon.

The Intera 3000 pump is the only implantable pump for HAI therapy approved in the U.S. that provides a constant flow. Its safety and effectiveness are supported by randomized controlled trial data that demonstrate the clinical benefits of HAI therapy for patients with unresectable colorectal metastases to the liver, both before and after resection. The results from these trials have shown that HAI therapy significantly improves tumor response, delays progression, and enhances overall survival compared to systemic chemotherapy. Additionally, combining HAI with systemic chemotherapy may extend survival and increase the likelihood of conversion to resection in both chemotherapy-naïve and previously treated patients. Ongoing Phase II and III studies are examining the use of HAI therapy in larger patient populations for first-line, second-line, and adjuvant treatments after surgery.

"Liver cancer is a leading cause of cancer-related death, and we are committed to providing meaningful solutions to safely and effectively treat various forms of this disease with minimal systemic side effects and improved outcomes for patients," said Peter Pattison, president, Interventional Oncology and Embolization, Boston Scientific. "Interest in HAI therapy has grown in the oncology community given improved techniques, positive clinical results and ongoing trials. We believe this acquisition will enable us to provide a more comprehensive set of solutions to physicians and their patients to treat both primary and metastatic forms of liver cancer."

Related Links:
Boston Scientific Corporation
Intera Oncology

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
LED Examination Lamp
Clarity 50 LED
New
Ultrasonic Cleaner
Cole-Parmer Ultrasonic Cleaner with Digital Timer

Print article

Channels

Critical Care

view channel
Image: The UbiqVue 2A Multiparameter System is based around a wearable ciosensor with chest-based SpO2 (Photo courtesy of LifeSignals)

Multiparameter System Featuring Wearable Biosensor Enables Continuous, Near Real-Time Patient Monitoring

A novel cloud-based system featuring a wearable biosensor with chest-based SpO2 monitoring enables continuous patient monitoring across both hospital and out-of-hospital care settings. The UbiqVue 2A... Read more

Surgical Techniques

view channel
Image: The Toumai system has successfully completed over 200 human robotic telesurgery cases globally (Photo courtesy of MicroPort Medbot)

Surgical Robot System with Telesurgery Capability to Revolutionize Healthcare Delivery

Robotic telesurgery, or remote surgery, is a technique where a surgeon operates on a patient from a distance using a robot and telecommunication networks. This approach allows surgeons to conduct procedures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.